Dutch MedTech developer raises €6 million plus US market financing for wound treatment device

Plasmacure, a Nijmegen-based MedTech innovator and developer of the PLASOMA cold plasma system for complex wound treatment, today announced a €6 million Series A investment to scale globally and advance the adoption of PLASOMA as a next-generation solution for complex wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers.

The round saw participation from a strategic consortium led by U.S.-based Venture Medical, LLC. Venture Medical will also finance the regulatory and reimbursement pathways in the U.S. market, an effort expected to exceed €8.5 million. The funding consortium also includes Coöperatie VGZ, Noaber, and Stichting Triade, alongside existing shareholders EIC Fund and Oost NL.

“We are deeply motivated by the needs of the millions living with hard-to-heal wounds,” said Bjorn Sprengers, CEO of Plasmacure. “With this investment and our new strategic partners, we are in a strong position to bring PLASOMA to more patients worldwide. Our vision is to transform wound care; to improve outcomes and to give patients back their mobility, dignity, and freedom. With PLASOMA, we aim to set a new global standard in the treatment of complex wounds.”

Founded in 2014, Plasmacure B.V. looks to lead the shift from conventional chronic wound management to high-impact technological solutions. Its flagship product, PLASOMA, applies cold plasma to accelerate healing in complex wounds, reportedly demonstrating up to 2.5 times greater effectiveness than standard care.

Cold plasma is created by energising gas molecules, producing a highly effective antimicrobial agent capable of eliminating even antibiotic-resistant bacteria. It also stimulates blood flow and cell regeneration.

The PLASOMA pulser delivers controlled electric pulses to a disposable pad, generating cold plasma directly in the wound. According to the company, this initiates multiple healing mechanisms, accelerating recovery and reducing the burden of chronic wounds.

“We see PLASOMA as a transformative technology that redefines what’s possible in wound healing. By investing in Plasmacure and supporting its U.S. rollout, we are enabling clinicians to offer next generation care that is both innovative and accessible,” said John Schroeder, CEO of Venture Medical.

As global populations age and the prevalence of diabetes continues to rise, an estimated 5% of elderly individuals suffer from complex wounds; conditions that severely impact quality of life and often lead to amputation. Standard treatment approaches show limited effectiveness, contributing to wound chronicity and accounting for an estimated 2–4% of total healthcare expenditure – as per data provided by Plasmacure.

In a recent randomised controlled trial, PLASOMA demonstrated the ability to close up to 2.5 times more complex wounds than the current standard of care, according to the company.

Martijn Kers, Director of Healthcare Policy and Innovation at Coöperatie VGZ, added: “At VGZ, we are committed to meaningful care: care that demonstrably works and improves the quality of life for our members. Plasmacure is a prime example of this. Last year, we nominated Plasmacure for the VGZ Award: Healthcare Innovator of the Future, an initiative that recognises and encourages promising healthcare startups. We see great potential in PLASOMA to significantly improve care for people with chronic wounds.”

The post Dutch MedTech developer raises €6 million plus US market financing for wound treatment device appeared first on EU-Startups.